Skip to Content

Bepreve Approval History

  • FDA approved: Yes (First approved September 8th, 2009)
  • Brand name: Bepreve
  • Generic name: bepotastine
  • Dosage form: Ophthalmic Solution
  • Company: ISTA Pharmaceuticals, Inc.
  • Treatment for: Conjunctivitis, Allergic

Bepreve (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis.

Development History and FDA Approval Process for Bepreve

Sep  9, 2009Approval Ista Pharmaceuticals' Bepreve Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
Jun 28, 2009Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Jun  2, 2009ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Jan 15, 2009ISTA Pharmaceuticals' New Drug Application for Bepreve Accepted for Review by U.S. Food and Drug Administration
Nov 14, 2008ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.